8.7.2024 NICE recommends pembrolizumab for advanced stomach cancers

“The National Institute for Health and Care Excellence (NICE) has recommended the use of the immunotherapy drug pembrolizumab (also known as Keytruda) as an option for people with advanced gastric cancer.

The recommendation is for those with advanced gastric or gastro-oesophageal cancers that are inoperable or have spread to other parts of the body, and express a protein called PD-L1. “